Sign In
Buy CCK
$121.66
+1.79 (+1.49%)
At Close: Aug 04, 2026
CROWN HOLDINGS SCHEDULES FOURTH QUARTER 2024 EARNINGS CONFERENCE CALL
01:25pm, Monday, 06'th Jan 2025
TAMPA, Fla. , Jan. 6, 2025 /PRNewswire/ -- Crown Holdings, Inc. (NYSE:CCK) will release its earnings for the fourth quarter ended December 31, 2024, after the close of trading on the New York Stock Ex
Crown Castle: I Bought The 52-Week Lows, Getting A Yield Of 7%
11:25am, Saturday, 04'th Jan 2025
I started a position in Crown Castle Inc. (CCI) due to its undervaluation, high dividend yield of 7%, and strong business model with significant barriers to entry. Despite a 57.24% decline from its al
Crown Castle: Attractive Upside Potential, Nearly 7% Dividend Yield
04:51am, Friday, 03'rd Jan 2025
Crown Castle, a leading communications infrastructure REIT, has lagged behind the sector and broader markets over the past year. This underperformance has persisted despite strong fundamentals, includ
Crown88 Renews Partnership with Taiwanese Influencer Avis for Year 2025
01:46pm, Sunday, 29'th Dec 2024
Singapore, Singapore--(Newsfile Corp. - December 29, 2024) - Crown88 , Singapore's largest online gaming platform since 2010, is pleased to announce the renewal of its successful partnership with Taiw
4 Reasons That Make Crown Castle Stock a Solid Pick for Your Portfolio
11:36am, Friday, 27'th Dec 2024
Amid rising wireless connectivity usage, CCI's efforts to augment its tower business, as well as fiber and small cells, bode well.
Is Crown Holdings (CCK) Stock Undervalued Right Now?
10:41am, Friday, 27'th Dec 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Crown CEO Issues Update Letter to Shareholders
04:30pm, Thursday, 26'th Dec 2024
Special Meeting of Stockholders To Approve Reverse Stock Split To Be Held on January 14th at 10:00 a.m. ET Special Meeting of Stockholders To Approve Reverse Stock Split To Be Held on January 14th at
Here's Why Crown Holdings (CCK) is a Strong Value Stock
10:40am, Monday, 23'rd Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Crown Completes Construction of First-of-Its-Kind Slant Well in Mexico
09:43am, Monday, 23'rd Dec 2024
LOS ANGELES, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company”), a leading provider of innovative technology infrastructure solutions that benefi
Crown's Element 82 Secures Two New Lead Pipe Inspection Projects in New York
09:15am, Tuesday, 17'th Dec 2024
LOS ANGELES, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Crown Electrokinetics Corp. (NASDAQ: CRKN) ("Crown" or the "Company”), a leading provider of innovative technology infrastructure solutions that benefi
Crown Castle Stock: A Golden Opportunity Near 52-Week Lows For Long-Term Investors
07:32pm, Sunday, 15'th Dec 2024
Crown Castle (CCI) stock is trading near 52-week lows, presenting an attractive entry point for long-term investors with a robust 6.45% dividend yield. CCI's strategic focus on small cells and 5G infr
Is the Options Market Predicting a Spike in Crown Holdings (CCK) Stock?
09:35am, Thursday, 12'th Dec 2024
Investors need to pay close attention to Crown Holdings (CCK) stock based on the movements in the options market lately.
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share
08:00am, Thursday, 12'th Dec 2024
Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn. , Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative lea
Is Crown Holdings (CCK) a Great Value Stock Right Now?
10:46am, Wednesday, 11'th Dec 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Revance agrees to lower-priced buyout offer by Crown Laboratories
09:12am, Monday, 09'th Dec 2024
Anti-wrinkle injection maker Revance Therapeutics has agreed to be bought for $3.10 per share by privately held Crown Laboratories, instead of $6.66 per share agreed previously, the two companies said
